Disruptive drugs for aging diseases and conditions
Topadur Pharma AG
Incorporated
10.03.2015Headquarters
SchlierenSupport
TOPADUR is a a clinical-stage biopharmaceutical start-up company developing disruptive therapies for aging diseases. The company developed the DualTOP™ technology platform consisting of new dual-acting drugs that increase the levels of cGMP to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. TOPADUR’s R&D portfolio consists of promising candidates in regenerative medicine, oncology, ophthalmology and medical aesthetics. The DualTOP™ technology will contribute to promoting long healthy life. Topadur Pharma is preparing for an IPO in Switzerland for 2024/25
News
Management transitions with industry veterans (startupticker.ch)
Bio Europe in Stockholm hosts 33 Swiss companies (startupticker.ch)
Oshen supports Topadur in the development of a treatment for alopecia (startupticker.ch)
Innosuisse funded 45 Start-up innovation projects (startupticker.ch)
Clinical progress for three Biotechs (startupticker.ch)
A decent representation at BIO-Europe (startupticker.ch)
Innosuisse Scale-up Coaching programme to boost 17 start-ups (startupticker.ch)
Seasoned leaders for five startups (startupticker.ch)
Four start-ups secure funding for their innovation projects (startupticker.ch)
TOP 100 Satellite Event: 5 TOP 100 Swiss Startups pitch to Credit Suisse investors (TOP 100)
Topadur records positive results (startupticker.ch)
Daniel Vasella joins Topadur (startupticker.ch)
Topadur submits clinical trial application (startupticker.ch)
Eleven Swiss start-ups on the virtual BIO Digital stage (startupticker.ch)
Ten healthcare startups compete for a ticket to the Silicon Valley (startupticker.ch)
Four Swiss startups to explore China (startupticker.ch)
Venturelab and digitalswitzerland present top 13 startups to international investors (startupticker.ch)
Die Gewinner des Swiss Economic Award stehen fest (startupticker.ch)
Ten startup founders are set for China (startupticker.ch)
Neun Startups für den SEF Award (startupticker.ch)
Milestones news
Start clinical phase 2a
Partnering development TOP-M119
Topadur receives EMA orphan drug designation
Topadur successful completed safety study with topical TOP-N53 formulation and starts planning the clinical phase 2 program
Topadur completed clinical phase 1 with lead product TOP-N53
Completed Ser C1
pre Series C 4.5 Mio $ (total equity raised 15 Mio $)
completed Series B
Documents
Videos and Presentations
Dual-mode-of- action
Startup Champions: venture leaders USA 2016 kick-off event (April 21st, 2016, EPFL)